Thrive Acquisition Corporation (THAC.U) Prices 15M unit IPO at $10/unit
- Wall Street rebounds after virus-related sell-off
- Here's What Analysts are Saying as Twitter (TWTR) Stock Erases Earlier Gains
- Moderna (MRNA) Stock Up 10% as WHO Says Omicron Covid Variant Poses 'Very High' Global RIsk
- 2 Reasons Why Citi Downgraded Merck (MRK) to Neutral Today, Opened a Negative Catalyst Watch
- Why EV Li Auto (LI) Stock Is Up 8% Today
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Thrive Acquisition Corporation (NASDAQ: THAC.U) today announced the pricing of its initial public offering of 15,000,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “THAC.U” beginning October 21, 2021. Each unit consists of one Class A ordinary share of the Company and one-half of one redeemable warrant with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “THAC” and “THAC.WS,” respectively. The offering is expected to close on October 25, 2021, subject to customary closing conditions.
Thrive Acquisition Corporation, led by CEO Charles Jobson, is a special purpose acquisition company formed with the purpose of entering into a business combination with one or more businesses. While the Company may pursue an initial business combination with a company in any sector or geography, it intends to focus its search on businesses within the global health and wellness industry.
BTIG, LLC is acting as the sole bookrunner for the offering. I-Bankers Securities, Inc. is acting as co-manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 2,250,000 units at the initial public offering price to cover over-allotments, if any.
The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained by contacting BTIG, LLC 65 East 55th Street, New York, NY 10022, or by email at ProspectusDelivery@btig.com.
A registration statement relating to the securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on October 20, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualigen Therapeutics (QLGN) Announces $8.82M Registered Direct Common Stock Offering
- AerSale Corporation (ASLE) Announces Cashless Redemption of All Public Warrants
- Sigilon Therapeutics (SGTX) Announces SIG-001 Trial is Placed on Clinical Hold
Create E-mail Alert Related CategoriesCorporate News, IPOs, SPAC
Related EntitiesDefinitive Agreement, IPO, BTIG, SPAC
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!